Kapila K. Anand - 29 Sep 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Director
Signature
/s/ Catherine S. Powell, as Attorney-in-Fact for Kapila K. Anand
Issuer symbol
ELAN
Transactions as of
29 Sep 2023
Net transactions value
+$14,375
Form type
4
Filing time
03 Oct 2023, 16:40:17 UTC
Previous filing
07 Jun 2023
Next filing
04 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Deferred Stock Units Award $14,375 +1,279 +29% $11.24 5,695 29 Sep 2023 Common Stock 1,279 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
F2 The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
F3 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $11.24 on September 29, 2023.